Eyenovia (NASDAQ:EYEN) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Eyenovia (NASDAQ:EYEN - Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

Eyenovia Stock Performance

Shares of EYEN stock traded down $0.24 during trading on Thursday, hitting $0.82. The company's stock had a trading volume of 1,652,935 shares, compared to its average volume of 1,110,166. Eyenovia has a 52 week low of $0.50 and a 52 week high of $3.64. The business has a fifty day moving average of $0.93 and a 200-day moving average of $1.42. The company has a market cap of $41.83 million, a PE ratio of -1.23 and a beta of 1.71. The company has a current ratio of 2.17, a quick ratio of 2.16 and a debt-to-equity ratio of 1.00.

Eyenovia (NASDAQ:EYEN - Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). During the same quarter in the previous year, the firm posted ($0.17) EPS. As a group, research analysts anticipate that Eyenovia will post -0.89 earnings per share for the current year.

Insider Activity at Eyenovia

In related news, major shareholder Stuart M. Grant purchased 100,000 shares of the business's stock in a transaction on Thursday, March 28th. The stock was acquired at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the acquisition, the insider now owns 5,430,715 shares of the company's stock, valued at approximately $5,322,100.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Eyenovia news, major shareholder Stuart M. Grant bought 100,000 shares of Eyenovia stock in a transaction dated Thursday, March 28th. The shares were purchased at an average cost of $0.98 per share, for a total transaction of $98,000.00. Following the acquisition, the insider now directly owns 5,430,715 shares in the company, valued at approximately $5,322,100.70. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Stuart M. Grant bought 50,000 shares of the business's stock in a transaction dated Tuesday, March 19th. The shares were bought at an average cost of $1.23 per share, for a total transaction of $61,500.00. Following the transaction, the insider now owns 5,330,715 shares in the company, valued at approximately $6,556,779.45. The disclosure for this purchase can be found here. Insiders have acquired 160,717 shares of company stock valued at $176,433 over the last ninety days. Insiders own 7.10% of the company's stock.

Hedge Funds Weigh In On Eyenovia

Several institutional investors have recently bought and sold shares of the business. Armistice Capital LLC purchased a new position in Eyenovia in the third quarter valued at $5,124,000. Vanguard Group Inc. lifted its stake in Eyenovia by 25.2% in the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company's stock valued at $1,765,000 after buying an additional 360,924 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company's stock worth $217,000 after purchasing an additional 205,390 shares in the last quarter. PFG Investments LLC acquired a new stake in shares of Eyenovia in the first quarter valued at about $69,000. Finally, Nations Financial Group Inc. IA ADV purchased a new stake in Eyenovia during the 4th quarter valued at about $84,000. 25.84% of the stock is owned by hedge funds and other institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.